



Cutting-edge cancer immunotherapy



MATWIN award "Best-in-class
therapeutic innovation" 2021

Bioserra2 – 7 Sep 2021

bpifrance

« Deeptech » 2020

Tolllys is a private company developing rationally designed TLR3 agonists against cancer



UMR Inserm 1052 CHRS 5286 Centre Léon Bérard



TL-532
Lead- candidate
70 base pair dsRNA




Proof-of-concept
In vitro
In vivo
Ex vivo

TLR3 receptor biology

2015-2016: TLR3 research

2017-2018 discovery and patent filing

2019-2020: preclinical POC



Vincent Charlon, PhD, Chief Executive Officer

Philippe Guillot-Chêne, PharmD, Chief Business Officer

Nasser Azli, MD, Chief Medical Officer

Bettina Werle, PhD, HDR, Chief Scientific Officer

Amina Zinaï, MD, Head of Clinical development

Caroline Ballet, PhD, R&D Project Leader

Marc Bonnin, PhD, Head of Discovery Unit

Sylvain Thierry, PhD, Head of Translational Research

Nelly Vey, PhD, Clinical Translational Leader

Denis Ravel, PhD, Toxicology

Christian Frauendorf, PhD, RNA CMC expert

Marie-Aude Ohresser, PharmD, Regulatory

Marc Lemaitre, PhD, RNA CMC expert (US)



• Board of Directors



Philippe Goupit PharmD, Chairman
Ex-VP Corporate licenses and M&A Sanofi



Jacques-François Martin, MBA HEC
Co-founder, ex-CEO Institut Merieux



Celline Saint Olive
CEO Norelker



Dino Dina, MD,
Ex CEO Dynavax



Dominique Rigal, MD
Co founder hematologist

• Scientific Advisory Board



Jean Yves Blay, MD
Director Centre Léon Bérard
President Unicancer



Jean-Pierre Abastado, PhD
ex-Head R&D oncology
Servier



Jean Pierre Armand, MD
Oncologist, Institut G Roussy




Bruno Osterwalder, MD
Oncologist, clinical development
Roche, Merck AG licensing



Stanley Plotkin, MD
Professor emeritus
Immunology


Direct Apoptosis



Immune Stimulation




Micro-environment Switch



Short term

Long term


Anti-tumoral effect



Immune cell death



In-situ autovaccination




Prevention of recurrence

For more information
see our video at
www.tollys.fr

Single TL-532
Treatment

Anti-tumor
effect

Prevents recurrence after rechallenge with cancer cells
In-situ autovaccination



TL-532 induces **lifelong tumor autovaccination** *in vivo* in mice

Research



Lead-optimization



Preclinical safety / CMC



Clinical Phase 1

TL-532 intra-tumoral

TL-532s optimized for intravenous use

TL-532v vectorized

TL-vir virology

***Clinical Proof-of-Concept
bladder + cutaneous tumors***

→ Multiple potential products and indications

- **Bureaux et laboratoires co-localisés, après 5 ans d'hébergement au CLB et en ville**
- **Proximité avec le CRCL, le CLB et les Hôpitaux**
- **Mutualisations et échanges possibles avec les sociétés du Bioparc**



www.tollys.fr

[**contact@tollys.fr**](mailto:contact@tollys.fr)

Tollys SAS

Bioserra2

60F Avenue Rockefeller

69008 Lyon, France